A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections

  • Matthews, P.
  • Alpert, M.
  • Rahav, G.
  • Rill, D.
  • Zito, E.
  • ... Pai, H.
  • 외 108명
Citations

WEB OF SCIENCE

26
Citations

SCOPUS

32

초록

Background: Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with significant morbidity and mortality.Methods: In this phase 3b/4 parallel, randomized, open-label, comparative study, 531 subjects with cSSSI received tigecycline (100 mg initial dose, then 50 mg intravenously every 12 hrs) or ampicillin-sulbactam 1.5-3 g IV every 6 hrs or amoxicillin-clavulanate 1.2 g IV every 6-8 hrs. Vancomycin could be added at the discretion of the investigator to the comparator arm if methicillin-resistant Staphylococcus aureus (MRSA) was confirmed or suspected within 72 hrs of enrollment. The primary endpoint was clinical response in the clinically evaluable (CE) population at the test-of-cure (TOC) visit. Microbiologic response and safety were also assessed. The modified intent-to-treat (mITT) population comprised 531 subjects (tigecycline, n = 268; comparator, n = 263) and 405 were clinically evaluable (tigecycline, n = 209; comparator, n = 196).Results: In the CE population, 162/209 (77.5%) tigecycline-treated subjects and 152/196 (77.6%) comparator-treated subjects were clinically cured (difference 0.0; 95% confidence interval [CI]: -8.7, 8.6). The eradication rates at the subject level for the microbiologically evaluable (ME) population were 79.2% in the tigecycline treatment group and 76.8% in the comparator treatment group (difference 2.4; 95% CI: -9.6, 14.4) at the TOC assessment. Nausea, vomiting, and diarrhea rates were higher in the tigecycline group.Conclusions: Tigecycline was generally safe and effective in the treatment of cSSSIs.Trial registration: ClinicalTrials.gov NCT00368537.

키워드

CSSSIGlycylcyclineSkin and skin structure infectionTigecyclineSOFT-TISSUE INFECTIONSSTAPHYLOCOCCUS-AUREUSIN-VITROANTIMICROBIAL AGENTSPRACTICE GUIDELINESDISEASES SOCIETYVANCOMYCINEFFICACYGAR-936PHASE-3
제목
A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections
저자
Matthews, P.Alpert, M.Rahav, G.Rill, D.Zito, E.Gardiner, D.Pedersen, R.Babinchak, T.McGovern, P.C.Armstrong, P.Bailey, C.Berbel, G.Bernstein, J.Bordon, J.Bruno-Murtha, L.A.Caprioli, R.Casey, K.Chiang, T.Churukian, A.Flynn, W.Graham, D.Hao, Z.Kalassian, K.Kohler, R.Lee, J.Leeds, W.Lucasti, C.Malanoski, G.Ko, T.Minnaganti, V.Mogyoros, M.Morgan, B.Moss, C.Muluk, S.Murthy, R.O'Riordan, W.Pien, F.Polk, H.Augustinsky, J.B.Salvaggio, M.Smith, L.Smith, R.Scott, Stienecker R.Suh, B.Vazquez, J.Weiland, D.E.Wessolossky, M.Zenilman, J.Abraham, C.Nathan, R.Sanchez, P.Baird, I.Callahan, C.Schrock, C.G.Lau, W.Bochan, M.R.Somero, M.Klein, S.R.Bellows, C.D'Hooghe, A.Ceulemans, F.Gaillat, J.Garo, B.Eckmann, C.Haier, J.Suter, F.Bertani, A.Acin, F.Jim?nez-Mej?as, M.E.Blanes, I.Regueiro, D.S.Cakir, N.Saba, R.Giladi, M.Kanj-Sharara, S.Ahmed, al Thaqafi A.O.Ng, W.-M.Burd, A.Kurlekar, U.Rao, N.R.Devarajan, T.Choi, J.Kim, Y.Pai, H.Park, Y.-S.Kumar, S.Chow, T.S.Crisostomo, A.Erasmo, A.Low, J.Basson, Breedt, J.Matthews, Ross, D.P.Lin, H.-H.Liao, C.-H.Kung, H.-C.Chinswangwatanakul, V.Malathum, K.Tantawichien, T.Sergio, Ricardo Filho PenteadoCardoso, F.Gomez, R.F.Velazquez, D.F.Tinoco-Favila, J.C.Poirier, A.Valiquette, L.Weiss, K.Grimard, D.Embil, J.M.A.Sanche, S.E.Smith, K.Chouinard, S.Dolc?, P.
DOI
10.1186/1471-2334-12-297
발행일
2012-11
유형
Article
저널명
BMC Infectious Diseases
12
페이지
1 ~ 9

파일 다운로드